Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARAVONE vs TIGLUTIK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.
Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.
Treatment of amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS)
60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.
50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.
Terminal elimination half-life is 4.5-6 hours. In patients with moderate hepatic impairment, half-life may be prolonged up to 9 hours. No significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 9-15 hours, with a mean of 12 hours. Steady-state is reached within 5-7 days. Clinically, this supports twice-daily dosing.
Edaravone is metabolized primarily via glucuronidation by UGT1A6, UGT1A9, and UGT2B7, and also undergoes sulfation. It is not significantly metabolized by CYP450 enzymes.
Hepatic metabolism primarily via CYP1A2, with minor contributions from CYP3A4 and glucuronidation.
Primarily renal excretion as unchanged drug and metabolites (approximately 60-70% unchanged edaravone in urine). Minor fecal elimination (<10%).
Riluzole is primarily eliminated via hepatic metabolism, with <10% excreted unchanged in urine. Metabolites are eliminated renally (~85%) and fecally (~5%).
Approximately 90-92% bound to plasma proteins, primarily to albumin.
97% bound primarily to plasma proteins, including albumin and lipoproteins.
Volume of distribution is approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. Predominantly distributes in extracellular fluid.
Approximately 3.4 L/kg, indicating extensive tissue distribution, particularly into the CNS.
Oral bioavailability is approximately 50-60% due to first-pass metabolism. For the intravenous formulation (approved), bioavailability is 100% by definition.
Oral bioavailability is approximately 60% (range 36-76%) due to extensive first-pass metabolism. High-fat meals reduce AUC by 20% and Cmax by 45%.
No dose adjustment required for GFR ≥30 m L/min/1.73 m². Safety and efficacy not established for GFR <30 m L/min/1.73 m²; use with caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No specific guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to lack of data.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B), but use with caution.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for pediatric patients under 18 years of age. Safety and efficacy have not been established.
No specific dose adjustment required; pharmacokinetic studies show no significant differences in elderly patients. Monitor renal function as age-related decline may occur.
No specific dose adjustment recommended based on age alone; consider renal function and overall frailty. Monitor for adverse effects, particularly falls and dysphagia.
None.
None
Hypersensitivity reactions (e.g., urticaria, dyspnea) have been reported; discontinue if severe.,Monitor for sulfite sensitivity in patients with asthma (contains sodium bisulfite).,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Use with caution in moderate to severe hepatic impairment.
Hepatic injury (elevated transaminases, bilirubin),Neutropenia,Interstitial lung disease,Dizziness and somnolence
Hypersensitivity to edaravone or any of its excipients.,Severe renal impairment (Cr Cl <30 m L/min).
Hypersensitivity to riluzole or any component of the formulation,Concomitant use with tizanidine,Severe hepatic impairment (Child-Pugh class C)
No significant food interactions reported. No dietary restrictions known.
Avoid high-fat meals (e.g., fried foods, cheese, creamy sauces) within 1 hour before or 2 hours after dosing, as they increase absorption and may increase risk of side effects. Grapefruit juice may increase riluzole levels; avoid concurrent consumption.
Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal malformations (e.g., skeletal abnormalities) at doses below the human equivalent. Risk cannot be excluded for all trimesters.
FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefit justifies risk. Second/third trimesters: possible fetal growth restriction; avoid if possible.
No data on edaravone excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Excretion into human milk unknown; M/P ratio not established. Caution advised; consider discontinuing nursing or drug based on importance to mother.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Use only if potential benefit justifies risk to fetus; consider alternative treatments if pregnancy occurs.
No standard dose adjustments established; pharmacokinetics in pregnancy not studied; monitor clinical response and adjust based on tolerability.
Monitor for hypersensitivity reactions, including anaphylaxis; edema and gait disturbance are common adverse effects. Avoid use in patients with severe hepatic impairment. Administer intravenous infusion over 60 minutes; do not mix with other medications in the same bag. Renal function monitoring recommended.
Tiglutik (riluzole) is the first liquid formulation of riluzole, approved for ALS. It can be administered via feeding tube. Monitor liver function tests (ALT, AST) monthly for 3 months, then quarterly. Avoid use in patients with baseline transaminase elevations >3x ULN. Concomitant use with hepatotoxic drugs (e.g., NSAIDs, acetaminophen >3 g/day) requires caution. Has a high fat emulsion suspension; do not dilute.
This medication is used to slow the progression of ALS symptoms.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,You may experience swelling in the legs or difficulty walking; notify your doctor if these become severe.,Do not drive or operate heavy machinery until you know how the medication affects you.,Keep all appointments for infusion and blood tests to monitor your kidney function.
Take each dose at least 1 hour before or 2 hours after a meal to avoid food interactions.,Shake the bottle well for at least 30 seconds before each use.,Use the provided dosing syringe to measure the correct dose; do not use household spoons.,If you miss a dose, take it as soon as you remember unless it is close to the next dose; do not double-dose.,Report any yellowing of skin or eyes, dark urine, or abdominal pain immediately as signs of liver toxicity.,You may feel dizzy or lightheaded; avoid driving until you know how the drug affects you.
No interactions on record
No interactions on record
Common clinical questions about EDARAVONE vs TIGLUTIK KIT, answered by our medical review team.
EDARAVONE is a Amyotrophic Lateral Sclerosis Agent that works by Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.. TIGLUTIK KIT is a Amyotrophic Lateral Sclerosis Agent that works by Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARAVONE and TIGLUTIK KIT depend on the specific clinical indication. These are both Amyotrophic Lateral Sclerosis Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARAVONE is: 60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.. The standard adult dose of TIGLUTIK KIT is: 50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARAVONE and TIGLUTIK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARAVONE is classified as Category C. Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal mal. TIGLUTIK KIT is classified as Category C. FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.